Invasive laser acupuncture vs. electroacupuncture for non-specific chronic low back pain: protocol for a randomized clinical trial.

Researchers are conducting a study to compare two types of acupuncture treatment for chronic low back pain that has lasted at least three months. The study will include 90 patients who will be randomly assigned to receive either invasive laser acupuncture (ILA) or traditional electroacupuncture (EA). Invasive laser acupuncture uses a 650 nanometer laser inserted at acupuncture points, while electroacupuncture applies electrical stimulation through traditional needles. Both groups will receive treatment at the same acupuncture points on both sides of the lower back and hips, including points known as BL23, BL24, BL25, and GB30. Treatments will last 10 minutes and occur twice weekly for four weeks, totaling eight sessions. The main goal is to measure pain reduction one week after completing treatment using a standard pain scale. Researchers will also track disability levels, quality of life, and any side effects throughout the study. This is a protocol paper, meaning the study is planned but results are not yet available. Once completed, this research will help determine whether laser acupuncture is as effective as traditional electroacupuncture for chronic low back pain. If laser acupuncture proves effective, it could offer patients another non-drug treatment option, which may be particularly appealing for those who prefer avoiding medications or want to try different approaches to managing persistent back pain. If you're considering acupuncture for back pain, consult with a licensed acupuncturist who has experience treating musculoskeletal conditions.

This multicenter, randomized, single-blind controlled trial protocol compares 650 nm invasive laser acupuncture (ILA) to conventional electroacupuncture (EA) for non-specific chronic low back pain (NSCLBP). The study will randomize 90 patients (1:1 allocation) to receive either ILA or EA at bilateral acupoints BL23, BL24, BL25, and GB30. Treatment protocol consists of 10-minute sessions administered twice weekly for four weeks (total: 8 sessions). The primary outcome measure is change in Visual Analog Scale (VAS) score at one week post-treatment. Secondary outcomes include interim and follow-up VAS scores, Oswestry Disability Index, EQ-5D-5L quality of life assessment, responder rates, and safety monitoring. As this is a protocol publication, efficacy and safety data are pending trial completion. Clinical takeaway: This trial will provide comparative effectiveness evidence for ILA versus EA in NSCLBP management, potentially expanding non-pharmacological treatment options for this prevalent condition if ILA demonstrates non-inferiority or superiority to conventional EA.